Bicycle Therapeutics plc (NASDAQ:BCYC) CFO Alethia Young Sells 1,395 Shares

Bicycle Therapeutics plc (NASDAQ:BCYC) CFO Alethia Young sold 1,395 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $19,655.55. Following the completion of the sale, the chief financial officer now directly owns 45,605 shares in the company, valued at approximately $642,574.45. This trade represents a 2.97 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Bicycle Therapeutics Stock Down 0.1 %

NASDAQ:BCYC traded down $0.01 during mid-day trading on Monday, reaching $14.88. 289,310 shares of the stock were exchanged, compared to its average volume of 435,603. The stock has a market capitalization of $1.03 billion, a P/E ratio of -4.52 and a beta of 0.92. Bicycle Therapeutics plc has a 1 year low of $12.17 and a 1 year high of $28.67. The company has a 50 day simple moving average of $19.27 and a 200-day simple moving average of $21.86.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. During the same period last year, the firm posted ($1.26) earnings per share. The company’s revenue for the quarter was down 50.0% compared to the same quarter last year. As a group, research analysts predict that Bicycle Therapeutics plc will post -3.05 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BCYC. Assetmark Inc. purchased a new position in shares of Bicycle Therapeutics during the third quarter worth about $34,000. GAMMA Investing LLC lifted its position in Bicycle Therapeutics by 105.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after acquiring an additional 1,038 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after acquiring an additional 2,918 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Bicycle Therapeutics by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after purchasing an additional 1,782 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Bicycle Therapeutics in the second quarter valued at approximately $206,000. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a research report on Friday, November 1st. B. Riley dropped their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Stephens initiated coverage on Bicycle Therapeutics in a report on Friday, November 8th. They set an “equal weight” rating and a $25.00 price target for the company. JMP Securities dropped their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a report on Wednesday, December 18th. Finally, Needham & Company LLC reissued a “buy” rating and set a $38.00 target price on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Bicycle Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.25.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.